» Articles » PMID: 25336498

Adrenalectomy is Comparable with Medical Treatment for Reduction of Left Ventricular Mass in Primary Aldosteronism: Meta-analysis of Long-term Studies

Overview
Journal Am J Hypertens
Date 2014 Oct 23
PMID 25336498
Citations 20
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Primary aldosteronism (PA) is associated with an increase in left ventricular (LV) mass beyond the amount needed to compensate the hypertension-related workload. Available evidence suggests effectiveness of surgical treatment of PA in decreasing LV mass, whereas data on medical treatment are controversial. We have conducted a meta-analysis of long-term follow-up studies on surgical and medical treatment of PA to compare the effects of treatments on LV mass.

Methods: Medline and Cochrane searches were performed including the following words: hyperaldosteronism, left ventricular mass, mineralocorticoid receptor antagonists, surgery, adrenalectomy, and follow-up studies. Studies published within 2013 focusing on cardiac effects of treatment and follow-up longer than 6 months were selected. Data extraction was performed independently by 2 authors.

Results: Of 61 retrieved articles, 4 were included in the analysis. These studies enrolled 355 patients with PA who had an average follow-up of 4.0 years after unilateral adrenalectomy (n = 178) or treatment with mineralocorticoid receptor antagonists (n = 177). Despite greater effect of surgery over medical treatment in reducing blood pressure, meta-analysis of the selected studies demonstrated no significant difference in LV mass change between patients with PA who were treated with mineralocorticoid receptor antagonists or adrenalectomy (standard mean difference = 0.130; 95% confidence interval = -0.085 to 0.345; P = 0.24; I2 = 0%).

Conclusions: Available evidence indicates that reduction of LV mass is not different in PA patients treated with adrenalectomy or mineralocorticoid receptor antagonists.

Citing Articles

Shifting paradigms in primary aldosteronism: reconsideration of screening strategy via integrating pathophysiological insights.

Kitamoto T, Ruike Y, Koide H, Inoue K, Maezawa Y, Omura M Front Endocrinol (Lausanne). 2025; 15:1372683.

PMID: 39877848 PMC: 11772158. DOI: 10.3389/fendo.2024.1372683.


Comparison of echocardiographic findings in patients with aldosterone-producing adenomas: adrenalectomy versus mineralocorticoid receptor antagonists.

Haze T Hypertens Res. 2024; 48(2):816-818.

PMID: 39609647 DOI: 10.1038/s41440-024-02008-8.


Evaluating the effects of adrenalectomy and mineralocorticoid receptor antagonist on cardiac remodeling and diastolic function in patients with aldosterone-producing adenoma.

Chang Y, Wu X, Chen T, Chen U, Liao C, Lai T Hypertens Res. 2024; 48(2):529-539.

PMID: 39448809 DOI: 10.1038/s41440-024-01946-7.


Predicting the resolution of hypertension following adrenalectomy in primary aldosteronism: Controversies and unresolved issues a narrative review.

Marzano L Langenbecks Arch Surg. 2024; 409(1):295.

PMID: 39354235 DOI: 10.1007/s00423-024-03486-7.


Adverse Effects of Aldosterone: Beyond Blood Pressure.

Brown J J Am Heart Assoc. 2024; 13(7):e030142.

PMID: 38497438 PMC: 11179780. DOI: 10.1161/JAHA.123.030142.